-
Subject Areas on Research
-
A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response.
-
A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.
-
A genomic- and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization.
-
Active immunization using dendritic cells mixed with tumor cells inhibits the growth of primary breast cancer.
-
Active immunotherapy for TNF-mediated inflammation using self-assembled peptide nanofibers.
-
Active-specific immunization against melanoma: is the problem at the receiving end?
-
Adoptive immunotherapy for malignant glioma.
-
Advanced prostate cancer: the future.
-
Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease.
-
Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1: Report from a meeting of the WHO-UNAIDS Vaccine Advisory Committee Geneva, 21-23 February 2000.
-
Assays for monitoring cellular immune responses to active immunotherapy of cancer.
-
Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.
-
CD19: a promising B cell target for rheumatoid arthritis.
-
Cellular and biological therapies of gastrointestinal tumors: overview of clinical trials.
-
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.
-
DNA and RNA modified dendritic cell vaccines.
-
Disrupting nicotine reinforcement: from cigarette to brain.
-
EGFRvIII as a promising target for antibody-based brain tumor therapy.
-
Experimental trials of immunotherapy for malignant melanoma.
-
Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer.
-
Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy.
-
How does sipuleucel-T alter our clinical practice?
-
Human immunodeficiency virus vaccines.
-
Immunotherapy for malignant melanoma with a tumor cell vaccine.
-
Immunotherapy of cancer using dendritic cells.
-
Immunotherapy of cancer with dendritic cell-based vaccines.
-
Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA.
-
Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells.
-
Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer.
-
Preparation of peptide-loaded dendritic cells for cancer immunotherapy.
-
Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts.
-
The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif.
-
Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells.
-
Tumor cells cotransduced with B7.1 and gamma-IFN induce effective rejection of established parental tumor.
-
Tumor microenvironment and the immune response.
-
Tumors as elusive targets of T-cell-based active immunotherapy.
-
Vaccine Therapy, Oncolytic Viruses, and Gliomas.
-
Keywords of People